ERBB2 and neoplasm: Chemotherapy with trastuzumab was the main neoadjuvant treatment in patients with tumours that were HER2 IHC 3+ or IHC 2+ within the HER2 amplified group (ASCO/CAP FISH Groups 1, 2 and 3), while all patients within the HER2 non-amplified group (Groups 4 and 5) received chemotherapy alone.